RVMD
Revolution Medicines, Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables):
amplitud de titulares +17.6% ·
flujo de acciones -0.6% ·
nuevas posiciones netas +10.0%
· fórmula
Fragmentación de la titularidad: más titulares, participación agregada más pequeña
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q3 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 2.20M | $451.04M | n/a | n/a |
| Q2 2026 | 149 | +17 | 106.82M | $18.63B | +25 | −7 |
| Q1 2026 | 134 | +17 | 103.45M | $9.43B | +22 | −6 |
| Q4 2025 | 116 | +1 | 107.70M | $8.12B | +3 | −1 |
| Q3 2025 | 20 | +3 | 68.96M | $3.10B | +3 | −1 |
| Q2 2025 | 15 | 0 | 63.88M | $2.26B | n/a | n/a |
| Q1 2025 | 12 | +2 | 32.32M | $1.05B | +2 | n/a |
| Q4 2024 | 10 | -1 | 33.19M | $1.34B | n/a | −1 |
| Q3 2024 | 10 | -1 | 26.28M | $1.08B | n/a | −1 |
| Q2 2024 | 11 | n/a | 28.23M | $999.53M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (pasivo) | 15.66M | -0.6% | $731.47M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | Wellington Management ✦ | 9.81M | -4.3% | $458.29M | 0.1% | ▼ Trim | 6 | SEC ↗ ×9 |
| 3 | Fidelity (FMR) ✦ | 9.40M | +12.9% | $439.06M | 0.0% | ▲ Add | 2 | SEC ↗ ×4 |
| 4 | BlackRock ✦ (pasivo) | 8.33M | -3.9% | $388.91M | 0.0% | ▼ Trim | 2 | SEC ↗ ×16 |
| 5 | State Street Global Advisors ✦ (pasivo) | 5.25M | +11.3% | $245.39M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | JPMorgan Chase ✦ | 5.00M | n/a | $233.34M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 7 | T. Rowe Price ✦ | 4.47M | -15.7% | $181.08M | 0.0% | ▼ Trim | 6 | SEC ↗ ×3 |
| 8 | Geode Capital Management ✦ (pasivo) | 3.15M | +5.1% | $146.93M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 9 | Morgan Stanley ✦ | 1.43M | n/a | $67.00M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 10 | Citadel Advisors ✦ | 1.18M | -20.1% | $55.11M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 11 | D. E. Shaw & Co. ✦ | 2.27M | +7.2% | $38.37M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 12 | Adage Capital Partners ✦ | 1.24M | +38.4% | $34.82M | 0.1% | ▲ Add | 6 | SEC ↗ ×2 |
| 13 | Goldman Sachs Group ✦ | 738.03K | n/a | $34.47M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 14 | Millennium Management ✦ | 428.31K | -69.0% | $20.00M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 15 | Renaissance Technologies ✦ | 253.10K | +3.9% | $11.82M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 16 | Marshall Wace ✦ | 161.10K | +482.0% | $7.52M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 17 | Gotham Asset Management ✦ | 99.11K | Nuevo | $4.63M | 0.0% | New | 1 | SEC ↗ |
| 18 | AQR Capital Management ✦ | 70.29K | +368.1% | $3.24M | 0.0% | ▲ Add | 6 | SEC ↗ ×3 |
| 19 | Two Sigma Investments ✦ | 9.11K | Nuevo | $425,297 | 0.0% | New | 1 | SEC ↗ |
| 20 | Fisher Asset Management ✦ | 7.30K | Nuevo | $341,143 | 0.0% | New | 1 | SEC ↗ |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Gotham Asset Management | $4.63M | 0.0% |
| Two Sigma Investments | $425,297 | 0.0% |
| Fisher Asset Management | $341,143 | 0.0% |
Posición cerrada
| Norges Bank | $62.58M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 509 tenedores, 197.96M acciones, $18.53B declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer · 765 acc. · $158,600
Officer · 3.12K acc. · $625,885
Officer · 587 acc. · $117,400
Director · 910 acc. · $174,585
Director · 4.99K acc. · $959,805
Director · 1.50K acc. · $291,883
Director · 100 acc. · $19,515
Director · 2.65K acc. · $512,227
Officer · 1.76K acc. · $347,402
Officer, Director · 13.78K acc. · $2.75M
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología